Precision Oncology · mRNA · AI

Personalized
cancer vaccines
at software speed.

Elyra, our AI engine, converts patient genomic data into personalized vaccine blueprints — in days, not months, at a fraction of the cost.

Elyra Engine — Active
The Problem

Personalized cancer vaccines work.
The world just can't deliver them.

Months
Too Slow
Design pipelines take months
Current neoantigen design and manufacturing pipelines are measured in months. Cancer patients don't have months to wait.
$500K+
Too Expensive
Cost puts it out of reach
Current Western approaches cost $100K–$500K+ per patient. Accessible to almost no one outside of clinical trials.
Billions
Inaccessible
A global equity crisis
Billions of cancer patients globally have no access to personalized treatment options. Geography determines survival.
The bottleneck is no longer science. It's execution.
The Answer

Meet Elyra.

The AI engine that converts patient genomic data into personalized cancer vaccine blueprints — in days.

1
1
Sequence Tumor
Whole-exome sequencing extracts mutation data from patient tumor biopsy
2
2
AI Identifies Neoantigens
Elyra scans mutations to identify peptides the immune system can recognize
3
3
Elyra Selects Targets
Ranked by binding affinity, expression, and clonality — optimal antigen set selected
4
4
mRNA Blueprint Generated
Epitopes, linkers, UTRs, codon optimization — construct ready for synthesis
5
5
Mfg + Delivery
Hainan GMP production via JV partner. Patient treated within weeks
Days
Not months · Design time
$20–50K
Not $100K+ · Per patient
DNA in
Vaccine blueprint out
Timing

Why Now?

Three forces have converged to make this the right moment to build Helixion.

01
mRNA Is Proven
2B+
Doses delivered globally
COVID-19 validated mRNA at global scale. Regulatory frameworks exist. Manufacturing infrastructure is real. The platform works.
02
AI Has Crossed the Threshold
Days
Not months, to design
AlphaFold and LLMs can now predict neoantigen binding with clinical-grade accuracy. The design cost has collapsed. Elyra is possible today.
03
Hainan Is Open
Dec 2025
Full Free Trade Port
China's Boao Lecheng sandbox is live. Fast-track approvals, zero tariffs, GMP partners ready. Early commercial revenue is possible now.
The bottleneck is no longer science. It's execution — and that's what Helixion is built for.
Strategic Location

Why Hainan?
The perfect launchpad.

China's only Medical Special Zone — Boao Lecheng — gives Helixion a regulatory edge no Western competitor can replicate.

Regulatory Edge
Fast-track approvals for imported tech. Real-world data feeds NMPA nationwide rollout. No full Phase 3 needed upfront. 3–7 day approval turnaround.
Financing & Incentives
Full Free Trade Port since Dec 2025: zero tariffs on equipment. 15% corporate tax vs 25% on mainland. Talent subsidies. Foreign biotech FDI up 19.9% in 2025.
Go-To-Market Ready
400K+ medical tourists per year. AXA insurance covers advanced therapies — tourists become paying patients. GMP partners ready: Likang, Everest labs.
3–7
Days approval turnaround
15%
Corporate tax rate
400K+
Medical tourists / yr
$0
Tariffs on equipment
Competitive Moat

No competitor combines Elyra's AI speed + Hainan GMP + Canadian RTO. Helixion owns this intersection.

Traction

This is already happening.

Built & Validated
AI neoantigen design pipeline operationalEnd-to-end neoantigen → mRNA design system. Design timelines: days to weeks.
Built ✓
mRNA construct generationElyra engine running — AI-driven, fully integrated
Built ✓
Real-world feasibility testPipeline tested on a live oncology case. Confirmed: feasibility, speed, and low-cost design.
Validated ✓
Prototype — canine oncology modelDemonstrates AI workflow is viable. Human scaling underway.
Validated ✓
Hainan JV pathway & GMP partnerLikang model identified. Lecheng commercial pathway validated.
Mapped ✓
Ready to Deploy
RTO listing — TSXV or CSEReverse Takeover structure. 3–6 month fast listing timeline.
In Progress
First human patient cohortTargeted for 2026. Lecheng commercial patients.
2026
Commercial patients — LechengRevenue from medical tourism. Not contingent on regulatory approval.
2026
Series A close — $10–25MConcurrent with RTO financing. 40% to Elyra build-out.
2026
Business Model

An inevitable progression.

Revenue begins in 2026 from Lecheng patients — not contingent on regulatory approval.

Phase 1
2026
Early Revenue
  • →First commercial patients in Lecheng (medical tourism)
  • →JV signed with Hainan GMP partner
  • →RTO listing & $10–25M raise
  • →Real-world data collection begins
→
Phase 2
2027–2028
Expansion
  • →100+ patients treated
  • →NMPA approval pathway active
  • →Pan-Asia commercial launch
  • →Data packages for global licensing
→
Phase 3
2029+
Global Scale
  • →Global licensing & partnerships
  • →Combination therapy programs
  • →Big pharma co-development
  • →Multiple oncology indications
Built → Tested → Ready to Deploy
Market Opportunity

A rapidly expanding,
underserved market.

Personalized Cancer Vaccine Market (USD Millions)
$350M
2025
$510M
2026
$740M
2027
$1.05B
2028
$1.4B
2029
$1.75B
2030
↑ 44–45% CAGR · 2025–2030
44–45%
CAGR · Fastest-growing biotech segment
$141B
mRNA Therapeutics market by 2030
~$20K
Our target price vs $100K–$500K+ in West
400K+
Medical tourists through Lecheng annually
Team

Proven operators.
Repeat founders.
Cross-border experts.

Sean Clark and Marc van der Chijs built Hut 8 together. Helixion Therapeutics is their next chapter.

Sean Clark
Sean Clark
Chief Executive Officer
Serial Founder · Public Markets Veteran. CEO of Hut 8 — raised $100M, led TSX public listing. CEO & Founder, First Block Capital — first regulated crypto firm in Canada. Founder, Shoes.com — pioneering Canadian e-commerce. Deep expertise in cross-border capital markets.
Hut 8 CEOTSX ListingFirst Block CapitalShoes.com
Marc van der Chijs
Marc van der Chijs
Chief Operating Officer
Serial Entrepreneur · China & Crypto Pioneer. Co-founder Tudou.com — China's leading video platform, listed NASDAQ, sold to Alibaba. Co-founder Hut 8 Mining — largest Bitcoin miner in North America. 13 years in China; deep Hainan operational network.
Tudou → AlibabaHut 8 Co-founderFirst Block Capital13 Yrs China
?
Chief Scientific Officer
To Be Announced
PhD in Oncology, Immunology, or mRNA biology. Neoantigen vaccine platform experience. IND-stage regulatory background. Hainan / NMPA pathway connections a plus. We are actively recruiting the world's best.
mRNA BiologyNeoantigen VaccinesIND ExperienceNMPA Pathway
The Ask

We are building the
intelligence layer
for cancer therapy.

$10–25M
Series A · Concurrent with TSXV / CSE RTO · 3–6 month listing

We are raising $10–25M to reach first human patients in Hainan in 2026. Revenue from Lecheng patients is not contingent on full regulatory approval.

40%
Elyra Platform Build-Out
Neoantigen pipeline & compute infrastructure
30%
Hainan JV & Regulatory
Setup, NMPA pathway, first patient cohorts
20%
Team / Legal / Compliance
Canada–China cross-border structure
10%
Working Capital
Bridge to milestones

Get in touch

We welcome conversations with healthcare-focused VCs, family offices, and strategic investors aligned with the intersection of AI, oncology, and Asian markets.

Founder & CEO
Sean Clark
Location
Vancouver, BC · Canada
HELIXION
© 2026 Helixion Therapeutics Inc. — Vancouver, BC, Canada